Development of Antiepileptic Drugs throughout History: From Serendipity to Artificial Intelligence
María Gabriela Corrales-Hernández,
Sebastián Kurt Villarroel-Hagemann,
Isabella Esther Mendoza-Rodelo,
Leonardo Palacios-Sánchez,
Mariana Gaviria-Carrillo,
Natalia Buitrago-Ricaurte,
Santiago Espinosa-Lugo,
Carlos-Alberto Calderon-Ospina,
Jesús Hernán Rodríguez-Quintana
Affiliations
María Gabriela Corrales-Hernández
Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Sebastián Kurt Villarroel-Hagemann
Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Isabella Esther Mendoza-Rodelo
Semillero de Investigación en Neurociencia, Semineuros, Universidad del Rosario, Bogotá 111221, Colombia
Leonardo Palacios-Sánchez
Neuroscience Research Group (NeURos), NeuroVitae Center for Neuroscience, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Mariana Gaviria-Carrillo
Neuroscience Research Group (NeURos), NeuroVitae Center for Neuroscience, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Natalia Buitrago-Ricaurte
School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Santiago Espinosa-Lugo
Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Carlos-Alberto Calderon-Ospina
Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
This article provides a comprehensive narrative review of the history of antiepileptic drugs (AEDs) and their development over time. Firstly, it explores the significant role of serendipity in the discovery of essential AEDs that continue to be used today, such as phenobarbital and valproic acid. Subsequently, it delves into the historical progression of crucial preclinical models employed in the development of novel AEDs, including the maximal electroshock stimulation test, pentylenetetrazol-induced test, kindling models, and other animal models. Moving forward, a concise overview of the clinical advancement of major AEDs is provided, highlighting the initial milestones and the subsequent refinement of this process in recent decades, in line with the emergence of evidence-based medicine and the implementation of increasingly rigorous controlled clinical trials. Lastly, the article explores the contributions of artificial intelligence, while also offering recommendations and discussing future perspectives for the development of new AEDs.